At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 1,041 enrolled
Drug / intervention
Nivolumab in combination with Ipilimumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3b/4 Safety Trial of Flat Dose Nivolumab In Combination With Ipilimumab in Participants With Non-Small Cell Lung Cancer
In Brief
A Phase 4 clinical trial evaluating Nivolumab in combination with Ipilimumab for Lung Cancer. Completed, enrolled 1,041 participants across 136 sites in 21 countries.
Detailed Summary
A study to evaluate the safety of Nivolumab given in combination with Ipilimumab in patients with advanced cancers. The initial group will enroll patients with newly diagnosed Stage 4 or non-small cell lung cancer that has come back.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer
CountriesArgentina, Belgium, Brazil, Canada, Chile, Czechia, France, Germany, Greece, Hungary, Italy, Mexico, Netherlands, Poland, Romania, Russia, Spain, Switzerland, Turkey (Türkiye), United Kingdom, United States
Collaborators--
Timeline
Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedAug 2016
Enrollment StartOct 2016
Primary CompletionMay 2022
TodayJul 2026
First PostedAug 17, 2016
Enrollment StartOct 5, 2016
Primary CompletionMay 13, 2022
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 9.9 years ago
Interventions
Nivolumab in combination with Ipilimumabdrug
Specified dose on specified days